Department of Medicine

Medicine & Life Sciences

1. Alleles 16%
2. Anti-Bacterial Agents 12%
3. Antibodies 17%
4. Antigens 27%
5. Antiviral Agents 12%
6. Armenia 20%
7. Asialoglycoprotein Receptor 13%
8. Autoantibodies 12%
9. Autoimmune Hepatitis 27%
10. Biopsy 15%
11. Bone Fractures 13%
12. Calculi 11%
13. Celiac Disease 17%
14. Cellular Immunity 15%
15. Central Asia 15%
16. Centromere 11%
17. Child 21%
18. Chromatin 45%
19. Chromosomal Position Effects 16%
20. Chromosomes 14%
21. Chronic Hepatitis 17%
22. Coronavirus 21%
23. Cost-Benefit Analysis 13%
24. Cross-Sectional Studies 11%
25. Cytokines 14%
26. Delivery of Health Care 13%
27. Diabetes Mellitus 12%
28. Drosophila 18%
29. Drosophila heterochromatin protein 1 18%
30. Endometrial Neoplasms 12%
31. Endometriosis 16%
32. Epigenomics 27%
33. Epitopes 15%
34. Euchromatin 12%
35. Fertility Preservation 11%
36. Genes 21%
37. Guidelines 11%
38. Hepacivirus 25%
39. Hepatitis 16%
40. Hepatitis A virus 11%
41. Hepatitis B 17%
42. Hepatitis B Surface Antigens 17%
43. Hepatitis B virus 18%
44. Hepatitis C 17%
45. Heterochromatin 97%
46. heterochromatin-specific nonhistone chromosomal protein HP-1 79%
47. Histone Code 17%
48. Histones 39%
49. HIV 38%
50. HIV-1 16%
51. HLA-DQB1 antigen 15%
52. In Vitro Techniques 11%
53. Incidence 14%
54. Infections 23%
55. Infertility 18%
56. Kazakhstan 100%
57. Kidney 23%
58. Kuwait 22%
59. Lithotripsy 11%
60. Liver 21%
61. Liver Diseases 12%
62. Lysine 23%
63. Massive Hepatic Necrosis 14%
64. Methylation 17%
65. Mortality 19%
66. Neoplasms 19%
67. Nuclear Envelope 17%
68. nuclear matrix protein 22 16%
69. Pain 12%
70. Pandemics 14%
71. Pediatrics 18%
72. Peptides 14%
73. Pharmaceutical Preparations 14%
74. Phenotype 12%
75. Population 21%
76. Pregnancy 11%
77. Prospective Studies 13%
78. Prostate 16%
79. Prostate-Specific Antigen 21%
80. Prostatic Hyperplasia 11%
81. Prostatic Neoplasms 22%
82. Proteins 39%
83. Rabbits 16%
84. SARS Virus 12%
85. Serum 26%
86. Spermatic Cord Torsion 17%
87. Spermatogenesis 13%
88. Stents 12%
89. Survivin 20%
90. T-Lymphocytes 39%
91. Testis 20%
92. Therapeutics 29%
93. Transplant Recipients 12%
94. Urinary Bladder Neoplasms 11%
95. Urine 24%
96. Urography 12%
97. Uterine Cervical Neoplasms 11%
98. Uterine Hemorrhage 13%
99. Virus Diseases 25%
100. Viruses 15%